USE OF A HIGH ADCC ANTI-CD20 ANTIBODY FOR THE TREATMENT OF WALDENSTROM'S DISEASE

摘要

The present invention relates to a monoclonal antibody directed against the CD20 antigen, said antibody having antibody-dependent cell-mediated cytotoxicity (ADCC) and / or an ability to activate enhanced FcγRIII-expressing effector cells, and having an Fc region at least 60% of the oligosaccharides are non-fucosylated, for use in the treatment of Waldenström disease.